Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) FCF Margin (2016 - 2023)

Spyre Therapeutics' FCF Margin history spans 7 years, with the latest figure at 2419.04% for Q2 2023.

  • For Q2 2023, FCF Margin rose 88864.0% year-over-year to 2419.04%; the TTM value through Mar 2024 reached 15806.83%, down 966812.0%, while the annual FY2023 figure was 11276.52%, 783376.0% down from the prior year.
  • FCF Margin reached 2419.04% in Q2 2023 per SYRE's latest filing, up from 8906.06% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 20.91% in Q2 2021 to a low of 10797.62% in Q4 2022.
  • Average FCF Margin over 3 years is 4075.09%, with a median of 2419.04% recorded in 2023.
  • Peak YoY movement for FCF Margin: plummeted -1026886bps in 2022, then surged 88864bps in 2023.
  • A 3-year view of FCF Margin shows it stood at 528.76% in 2021, then plummeted by -1942bps to 10797.62% in 2022, then soared by 78bps to 2419.04% in 2023.
  • Per Business Quant, the three most recent readings for SYRE's FCF Margin are 2419.04% (Q2 2023), 8906.06% (Q1 2023), and 10797.62% (Q4 2022).